CWP
ACAD icon

Concord Wealth Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Concord Wealth Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10
Closed -$163 – 958
2024
Q2 		$163 Buy
+10
New +$161 ﹤0.01% 799

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Concord Wealth Partners's ACAD Position: Q3 2024 in Review

Concord Wealth Partners sold out of Acadia Pharmaceuticals (ACAD) in Q3 2024, closing a stake of 10 shares — an estimated $163 sold.

Concord Wealth Partners first reported a position in ACAD in Q2 2024 and held it in 1 quarter. The position peaked at $163 in Q2 2024. 256 funds tracked by Wall St. Rank hold ACAD as of Q3 2024.

  • Concord Wealth Partners reported no remaining Acadia Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Concord Wealth Partners sold 10 Acadia Pharmaceuticals shares in Q3 2024, an estimated $163.
  • Concord Wealth Partners first reported a position in Acadia Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Concord Wealth Partners's Acadia Pharmaceuticals position peaked at $163 in Q2 2024.
  • 256 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2024.

Based on Concord Wealth Partners's 13F filing for Q3 2024, filed 24 Oct 2024.